
Caladrius Biosciences CLBS
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
8.69 M |
Market Cap[1] |
$ 25.8 M |
EBITDA (LTM) |
$ -18.1 M |
P/E (LTM) |
- |
P/S (LTM) |
151.957047 |
EPS (LTM) |
-1.91 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Eton Pharmaceuticals
ETON
|
$ 50.31 | 0.3 % | $ 1.35 B | Nasdaq Global Market | ||
|
ImmuCell Corporation
ICCC
|
$ 10.75 | 1.8 % | $ 97 M | Nasdaq Global Select Market | ||
|
Fulcrum Therapeutics
FULC
|
$ 3.65 | 0.14 % | $ 231 M | Nasdaq Global Market | ||
|
Kamada Ltd.
KMDA
|
$ 7.76 | 0.04 % | $ 447 M | Nasdaq Global Select Market | ||
|
IDEAYA Biosciences
IDYA
|
$ 32.85 | 0.25 % | $ 2.91 B | Nasdaq Global Select Market | ||
|
InflaRx N.V.
IFRX
|
$ 1.32 | 1.69 % | $ 88.8 M | Nasdaq Global Select Market | ||
|
Immutep Limited
IMMP
|
$ 3.18 | 0.93 % | $ 4.63 B | Nasdaq Global Market | ||
|
Mustang Bio
MBIO
|
$ 0.38 | 3.6 % | $ 1.87 M | Nasdaq Global Market | ||
|
Kala Pharmaceuticals
KALA
|
$ 0.19 | 0.57 % | $ 1.55 M | Nasdaq Global Select Market | ||
|
Mereo BioPharma Group plc
MREO
|
$ 0.3 | 1.32 % | $ 239 M | Nasdaq Global Select Market | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 78.59 | 1.4 % | $ 5.83 B | Nasdaq Global Select Market | ||
|
Karyopharm Therapeutics
KPTI
|
$ 0.39 | 11.2 % | $ 4.26 K | Nasdaq Global Select Market | ||
|
Seres Therapeutics
MCRB
|
$ 2.46 | 1.19 % | $ 21.8 M | Nasdaq Global Select Market | ||
|
MediWound Ltd.
MDWD
|
$ 11.85 | 0.08 % | $ 322 M | Nasdaq Global Select Market | ||
|
Precigen
PGEN
|
$ 6.39 | 0.54 % | $ 2 B | Nasdaq Global Select Market | ||
|
PolyPid Ltd.
PYPD
|
$ 4.72 | 1.45 % | $ 77.2 M | Nasdaq Global Select Market | ||
|
Rocket Pharmaceuticals
RCKT
|
$ 2.18 | 6.79 % | $ 242 M | Nasdaq Global Select Market | ||
|
Avidity Biosciences
RNA
|
$ 7.67 | 0.13 % | $ 1.06 B | Nasdaq Global Select Market | ||
|
Summit Therapeutics
SMMT
|
$ 14.63 | 1.59 % | $ 10.9 B | Nasdaq Global Select Market | ||
|
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | Nasdaq Capital Market | ||
|
Генетико
GECO
|
- | - | - | MOEX | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Scholar Rock Holding Corporation
SRRK
|
$ 39.9 | 2.63 % | $ 4.58 B | Nasdaq Global Select Market | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market | ||
|
Abcam plc
ABCM
|
- | - | $ 4.9 B | Nasdaq Global Select Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Affimed N.V.
AFMD
|
- | -34.95 % | $ 21.5 M | Nasdaq Global Select Market,SPB | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
- | -1.58 % | $ 28.1 M | Nasdaq Global Market | ||
|
Celyad Oncology SA
CYAD
|
- | - | $ 12.5 M | Nasdaq Global Market | ||
|
Gracell Biotechnologies
GRCL
|
- | - | $ 3.37 B | Nasdaq Global Select Market | ||
|
Galapagos NV
GLPG
|
- | - | $ 1.83 B | Nasdaq Global Select Market | ||
|
Tiziana Life Sciences PLC
TLSA
|
$ 1.05 | 0.95 % | $ 112 M | Nasdaq Global Market | ||
|
Teligent, Inc.
TLGT
|
- | -13.85 % | $ 16.1 M | Nasdaq Global Select Market | ||
|
Viela Bio, Inc.
VIE
|
- | - | $ 2.91 B | Nasdaq Global Select Market | ||
|
Aphria Inc.
APHA
|
- | -0.45 % | $ 4.87 B | Nasdaq Global Select Market | ||
|
Aerpio Pharmaceuticals, Inc.
ARPO
|
- | -0.90 % | $ 104 M | Nasdaq Capital Market | ||
|
Chiasma, Inc.
CHMA
|
- | -6.00 % | $ 238 M | Nasdaq Global Select Market | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
- | - | $ 376 M | Nasdaq Global Market | ||
|
Cellect Biotechnology Ltd.
APOP
|
- | 0.38 % | $ 12.9 M | Nasdaq Global Select Market | ||
|
AzurRx BioPharma, Inc.
AZRX
|
- | 2.07 % | $ 34.4 M | Nasdaq Capital Market | ||
|
Cerecor Inc.
CERC
|
- | -1.68 % | $ 283 M | Nasdaq Capital Market | ||
|
Constellation Pharmaceuticals, Inc.
CNST
|
- | - | $ 1.63 B | Nasdaq Global Select Market | ||
|
Auris Medical Holding Ltd.
EARS
|
- | -1.77 % | $ 39.2 M | Nasdaq Capital Market | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
- | 0.34 % | $ 2.98 B | Nasdaq Global Select Market,SPB | ||
|
ERYTECH Pharma S.A.
ERYP
|
- | 1.3 % | $ 27.7 M | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.